02:02 , Jun 9, 2018 |  BioCentury  |  Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together,...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
20:15 , Jul 7, 2017 |  BC Week In Review  |  Company News

NantWorks acquires Altor BioScience

The NantCell immuno-oncology subsidiary of NantWorks LLC (Los Angeles, Calif.) will acquire Altor BioScience Corp. (Miramar, Fla.) for an undisclosed sum. NantCell said for each share of Altor held, shareholders will receive either $2 in...
22:01 , Apr 7, 2017 |  BioCentury  |  Finance

Combo quest

By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow...
04:27 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Allogeneic aNK cells: Preliminary Ph II QUILT-3.009 data

Preliminary data from 3 patients with unresectable stage IIIB or IV MCC in the open-label, U.S. Phase II QUILT-3.009 trial showed that 2x10 9 IV aNK cells/m 2 for 2 consecutive days every 2 weeks...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Altor BioScience, NantKwest deal

Altor and NantKwest partnered to co-develop cancer therapies using Altor’s ALT-803 and ALT-801 in combination with NantKwest’s natural killer (NK) cell therapy platforms. ALT-803, an IL-15 mutant agonist complexed to an Fc fusion protein of...
07:00 , May 4, 2015 |  BioCentury  |  Emerging Company Profile

Adding to immune function

Admune Therapeutics LLC is developing a heterodimeric complex of IL-15 to boost the immune system's response to cancer immunotherapies by increasing the number of antitumor lymphocytes overall and in the vicinity of tumors. Tumors' responses...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

ALT-803: Phase I/II started

Altor began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate IV ALT-803 given on days 1, 8, 15 and 22 of a 6-week cycle for up to 4 cycles in about 50 patients. Shenzhen...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Altor BioScience, Shenzhen Beike Biotechnology deal

Altor granted Shenzhen Beike rights in China to develop and commercialize ALT-803 for human indications. The IL-15 mutant agonist complexed to an Fc fusion protein of IL-15 receptor a-chain ( IL-15RA ) is in Phase...
07:00 , Apr 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer IL-15 Patient studies suggest IL-15 could be useful for treating colorectal cancer. In a cohort of patients with colorectal cancer, carriers of an...